133 related articles for article (PubMed ID: 35737408)
1. A tale of two alleles: TP53 and transformation in MPNs.
Brierley C; Psaila B
Blood; 2022 Jun; 139(25):3567-3568. PubMed ID: 35737408
[No Abstract] [Full Text] [Related]
2. Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.
Monti P; Perfumo C; Bisio A; Ciribilli Y; Menichini P; Russo D; Umbach DM; Resnick MA; Inga A; Fronza G
Mol Cancer Res; 2011 Mar; 9(3):271-9. PubMed ID: 21343334
[TBL] [Abstract][Full Text] [Related]
3. Tailoring Chemotherapy for the African-Centric S47 Variant of TP53.
Barnoud T; Budina-Kolomets A; Basu S; Leu JI; Good M; Kung CP; Liu J; Liu Q; Villanueva J; Zhang R; George DL; Murphy ME
Cancer Res; 2018 Oct; 78(19):5694-5705. PubMed ID: 30115697
[TBL] [Abstract][Full Text] [Related]
4. JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
Xiao W; Rampal R; Zhang Y; Cimera R; Jungbluth AA; Arcila M; Roshal M; Park DC
Leukemia; 2018 Aug; 32(8):1842-1845. PubMed ID: 29743724
[No Abstract] [Full Text] [Related]
5. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity.
Cai KQ; Wu H; Klein-Szanto AJ; Xu XX
Gynecol Oncol; 2009 Jul; 114(1):18-25. PubMed ID: 19375154
[TBL] [Abstract][Full Text] [Related]
7. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
8. Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
Tracy I; Tapper W; Parker A; Gardiner A; Sadullah S; Pratt G; Copplestone A; Oscier D; Best OG
Br J Haematol; 2017 Sep; 178(5):824-826. PubMed ID: 27292869
[No Abstract] [Full Text] [Related]
9. TP53 codon 72 polymorphism and type 2 diabetes: a case-control study in South Indian population.
Punja HK; Nanjappa DP; Babu N; Kalladka K; Shanti Priya Dias B; Chakraborty G; Rao SM; Chakraborty A
Mol Biol Rep; 2021 Jun; 48(6):5093-5097. PubMed ID: 34181170
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis.
Fuhrken PG; Apostolidis PA; Lindsey S; Miller WM; Papoutsakis ET
J Biol Chem; 2008 Jun; 283(23):15589-600. PubMed ID: 18397889
[TBL] [Abstract][Full Text] [Related]
11. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
12. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.
Li B; An W; Wang H; Baslan T; Mowla S; Krishnan A; Xiao W; Koche RP; Liu Y; Cai SF; Xiao Z; Derkach A; Iacobucci I; Mullighan CG; Helin K; Lowe SW; Levine RL; Rampal RK
Blood; 2022 Jun; 139(25):3630-3646. PubMed ID: 35421216
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53
Polireddy K; Singh K; Pruski M; Jones NC; Manisundaram NV; Ponnela P; Ouellette M; Van Buren G; Younes M; Bynon JS; Dar WA; Bailey JM
Cancer Lett; 2019 Jul; 453():122-130. PubMed ID: 30946870
[TBL] [Abstract][Full Text] [Related]
14. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
Marcellino BK; Hoffman R; Tripodi J; Lu M; Kosiorek H; Mascarenhas J; Rampal RK; Dueck A; Najfeld V
Blood Adv; 2018 Dec; 2(24):3581-3589. PubMed ID: 30563882
[TBL] [Abstract][Full Text] [Related]
15. Different mutation profiles associated to P53 accumulation in colorectal cancer.
López I; P Oliveira L; Tucci P; Alvarez-Valín F; A Coudry R; Marín M
Gene; 2012 May; 499(1):81-7. PubMed ID: 22373952
[TBL] [Abstract][Full Text] [Related]
16. Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint.
Roy A; Lordier L; Pioche-Durieu C; Souquere S; Roy L; Rameau P; Lapierre V; Le Cam E; Plo I; Debili N; Raslova H; Vainchenker W
Haematologica; 2016 Dec; 101(12):1469-1478. PubMed ID: 27515249
[TBL] [Abstract][Full Text] [Related]
17. Presence of CD34
Duarte FB; DE Jesus Dos Santos TE; Barbosa MC; Moura ATG; DE Vasconcelos JPL; Rocha-Filho FD; Coutinho DF; Zalcberg I; Vasconcelos PRL; Garcia YDO; Lemes RPG
In Vivo; 2019; 33(1):277-280. PubMed ID: 30587636
[TBL] [Abstract][Full Text] [Related]
18. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
19. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
Slingerland JM; Jenkins JR; Benchimol S
EMBO J; 1993 Mar; 12(3):1029-37. PubMed ID: 8458321
[TBL] [Abstract][Full Text] [Related]
20. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.
Liu Z; Wan G; Heaphy C; Bisoffi M; Griffith JK; Hu CA
Mol Cell Biochem; 2007 Mar; 297(1-2):179-87. PubMed ID: 17119852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
